Brainomix, an Oxford-based developer of AI imaging tools for stroke and lung fibrosis, has extended its Series C round with a new £4.8m investment.
The new funding will support the expansion of the British biotech firm’s US operations, which currently consist of an extensive portfolio of FDA-cleared AI imaging solutions.
As well as expanding its US operations, the company is working towards the deployment of iys AI imaging platforms, Brainomix 360 Stroke and e-Lung, across multiple hospitals.
The company’s flagship product, Brainomix 360 Stroke is a fully automated imaging platform designed for acute stroke assessment. Brainomix 360 e-Lung, meanwhile, applies AI-driven CT biomarkers to identify, monitor, and predict disease progression in pulmonary fibrosis.
“Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time, underscoring the need for hospital technologies that support clinicians at the point of care,” said Dr Michalis Papadakis, co-founder and chief executive of Brainomix.
“With this investment extension, we are well-positioned to enhance customer support across the US and Europe, accelerating the seamless integration of our technology into existing clinical workflows and expanding access to life-saving treatments.”
The University of Oxford spinout secured its £14m Series C round in March of last year, which has now reached £18.8m, with the extension led by existing investors Parkwalk Advisors and Hostplus via the IP Group Hostplus Innovation Fund, and includes participation from a new U.S.-based investor, Modi Ventures.
“Brainomix has built an exceptionally strong platform backed by rigorous clinical validation and real-world evidence showing that Brainomix 360 Stroke can significantly increase endovascular thrombectomy treatment rates and reduce delays in patient triage and transfer, particularly in primary stroke centres,” said Modi Ventures general partner Sahir Ali.
“With e-Lung, Brainomix is developing a truly novel technology to accelerate the diagnosis of fibrosing lung disease, enabling earlier treatment options that can improve patient outcomes.”
